SCHEMBL4209986

SCHEMBL4209986

NCCC1CCOc2cc(OCc3cccc(F)c3)ccc21

nearest known ligand 0.57

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MAOB P27338 19/20 0.57
GRM5 P41594 3/20 0.57
MAOA P21397 5/20 0.45
PARP10 Q53GL7 1/20 0.43
FFAR1 O14842 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4210202 0.91 MAOB (0.59) MAOBGRM5MAOAPARP10FFAR1
SCHEMBL4219623 0.89 MAOB (0.56) MAOBGRM5MAOAFFAR1
SCHEMBL4206569 0.87 MAOB (0.62) MAOBGRM5MAOAFFAR1
SCHEMBL4213246 0.87 MAOB (0.55) MAOBGRM5MAOAPARP10FFAR1
SCHEMBL4208226 0.86 MAOB (0.54) MAOBGRM5MAOA
SCHEMBL4208256 0.84 MAOB (0.57) MAOBGRM5MAOAPARP10FFAR1
SCHEMBL4211601 0.84 MAOB (0.56) MAOBGRM5MAOAFFAR1
SCHEMBL4208377 0.82 MAOB (0.52) MAOBGRM5MAOAFFAR1
SCHEMBL4213691 0.82 MAOB (0.54) MAOBGRM5MAOAFFAR1
SCHEMBL4208728 0.82 MAOB (0.54) MAOBGRM5MAOAPARP10FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090005436-A1 Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives NEWRON PHARMACEUTICALS S.P.A. (IT) 2009-01-01 US claimed
EP-1863784-A1 SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES Newron Pharmaceuticals S.p.A. (IT) 2007-12-12 EP claimed
WO-2006102958-A1 SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES NEWRON PHARMACEUTICALS S.P.A. (IT) 2006-10-05 WO claimed
US-20090005436-A1 Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives NEWRON PHARMACEUTICALS S.P.A. (IT) 2009-01-01 US disclosed
EP-1863784-A1 SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES Newron Pharmaceuticals S.p.A. (IT) 2007-12-12 EP disclosed
WO-2006102958-A1 SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES NEWRON PHARMACEUTICALS S.P.A. (IT) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005436-A1 Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives MAOB, MAOA, AOC3 MAOB 1/4885GRM5 1809/4885MAOA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.